Fibromyalgia

Investigational adjunctive use; one small pilot suggests transient improvement in tender-point and quality-of-life scores. Not a primary treatment.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?: Not FDA-cleared for fibromyalgia. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for fibromyalgia is investigational.
Welche Evidenz existiert?: Tier C (investigational). Small uncontrolled case series report short-term improvement in tender-point pain after multiple sessions. There are no randomized controlled trials in fibromyalgia. Fibromyalgia trials are highly susceptible to placebo response. Evidence-based therapies — graded exercise, cognitive-behavioral therapy, duloxetine, milnacipran, pregabalin, and multidisciplinary pain management — remain first-line.
Hauptrisiken: Bleeding from each bite site for 6 to 24 hours after detachment
Bruising and tenderness across multiple body regions (because of widespread tender-point placement) for 5 to 10 days
Itching and irritation at bite sites for days to weeks
Local skin infection or, rarely, Aeromonas infection
Allergic reaction to leech saliva (uncommon)
Mild anemia with higher leech counts across repeated sessions
Temporary worsening of generalized pain or fatigue for 1 to 3 days (flare risk in centrally sensitized patients)
Small permanent scars at bite sites
Wer dies nicht in Betracht ziehen sollte: Patients on blood thinners (warfarin INR >2.0, DOACs, heparin)
Patients with hemophilia or other bleeding disorders
Patients with severe anemia (Hb <10 g/dL)
Patients with active depression, anxiety, or PTSD that has not been addressed (these are core fibromyalgia comorbidities and respond to evidence-based therapy)
Patients with a weakened immune system
Patients with another untreated inflammatory rheumatologic condition (rule out before attributing pain to fibromyalgia)
Was Sie Ihren Kliniker fragen sollten: Have I been worked up for other causes (rheumatologic, thyroid, sleep apnea)?
Have I completed adequate trials of evidence-based therapies (graded exercise, CBT, duloxetine, milnacipran, pregabalin)?
What evidence supports leech therapy for fibromyalgia specifically?
How many leeches and over how many sessions, and what is the cumulative bite-site burden?
What is the realistic chance of benefit, given high placebo response?
What is the practitioner's experience and Aeromonas-prevention plan?
What is the cost, and what does it commit me to?
Wann dringende medizinische Versorgung suchen: Bleeding from bite sites lasting more than 24 to 48 hours
Spreading redness, warmth, pus, or red streaks (cellulitis)
Fever above 38.0 C / 100.4 F or chills
New focal neurologic symptoms (weakness, numbness, vision change)
Severe worsening of suicidal ideation
Hives, throat tightness, or breathing difficulty

Was dies NICHT bedeutet

This is not FDA-cleared for fibromyalgia.
Mechanism rationale (anti-inflammatory, anti-nociceptive peptides) does NOT establish clinical efficacy in centralized pain.
Small uncontrolled series are not evidence beyond placebo, especially in a high-placebo-response condition.
Leech therapy is not a substitute for evidence-based pharmacologic and behavioral therapies.
Short-term symptom improvement in published series does not predict durable individual benefit.

Sicherheits-Querverweise

Clinical Profile

Category: musculoskeletal
ICD-10: M79.7
Safety tier: low

Evidence Summary

No controlled clinical trial or quantified case series of leech therapy for fibromyalgia has been published; use is investigational and mechanistic only. The speculative rationale is modulation of central sensitization via salivary peptides together with non-specific (placebo) effects, but there is no clinical evidence of benefit on validated measures such as the Fibromyalgia Impact Questionnaire or tender-point counts. ASH position: leech therapy is not a fibromyalgia treatment. First-line management is graded exercise, cognitive behavioral therapy, and (when needed) duloxetine, pregabalin, or amitriptyline. Leech therapy should not displace these and has no established role beyond exploratory research.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

Ilbay K et al. (2017), n=22

Detailed Trial Entries

3 trials indexed in the ASH RCT Library with full Study Profile, GRADE rating, and clinical implications:

Contraindications

Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
Hemophilia or other bleeding disorder
Severe anemia (Hb <10 g/dL)
Active bacteremia or sepsis
Known hypersensitivity to leech salivary proteins
Pregnancy (relative — first/third trimester)
Immunocompromised state with severe neutropenia
Severe depression with active suicidal ideation (manage psychiatric comorbidity first)

Related Conditions

Knee Osteoarthritis

Off-label use with three RCTs showing pain and function improvement comparable to NSAID gel at 3 months in mild-to-moderate symptomatic knee OA.

Thumb Carpometacarpal (CMC-1) Osteoarthritis

Off-label use with RCT evidence: single-session leech therapy reduces pain and improves function in CMC-1 (basal thumb) OA at 8 weeks.

Lateral Epicondylitis (Tennis Elbow)

Off-label use with two RCTs showing significant pain reduction at 7-12 weeks compared to topical NSAID and conventional physiotherapy.

Plantar Fasciitis

Off-label use with one RCT showing significant heel pain reduction at 6 weeks compared to conservative care.